ICT03 / ImCheck Therap - LARVOL DELTA

ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells (GlobeNewswire) - "ImCheck Therapeutics...announced the publication of preclinical data elucidating the fundamental role of butyrophilins (BTNs) in the activation of V gamma 9 V delta 2 (Vγ9Vδ2) T cells leading to an anti-tumor immune response in the peer-reviewed journal, Cell Reports. The publication, titled 'BTN2A1, An Immune-checkpoint Targeting Vγ9Vδ2 T Cell Cytotoxicity Against Malignant Cells' summarizes the findings of the interaction between specific BTN subtypes that efficiently activate Vγ9Vδ2 T cells, an important subset of cytotoxic γδ T cells...anti-BTN2A1-specific antibody is able to inhibit the cytotoxic function of the Vγ9Vδ2 T cells."

Preclinical • Oncology